Clinical Trial: Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration

U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07115667) titled 'Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration' on Aug. 03.

Brief Summary: This is a prospective, single-arm, single-center clinical trial designed to evaluate the safety and efficacy of radiation combined with a BCMA/CD3 bispecific antibody (CM336) in patients with solitary bone plasmacytoma (SBP) with mild bone marrow infiltration.

Study Start Date: Aug. 10

Study Type: INTERVENTIONAL

Condition: Solitary Bone Plasmacytoma Plasmacytoma of Bone Plasma Cell Disorders

Intervention: DRUG: BCMA/CD3 bispecific antibody (CM336)

Patients with solitary bon...